
Opinion|Videos|November 26, 2025
Key Objectives and Data from ASCENT-04
This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.
Advertisement
Episodes in this series

The ASCENT-04/KN-D19 study evaluated the efficacy of sacituzumab govitecan (SG) combined with pembrolizumab versus standard chemotherapy plus pembrolizumab in first-line treatment of metastatic TNBC. The study addressed a critical unmet need: improving outcomes in a population with historically limited options. SG has demonstrated benefit in the second-line setting, and combining it with immunotherapy upfront aimed to enhance clinical responses.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
5
















































































































